CLRB News and Press, Cellectar Biosciences Inc. From 03/12/21

The following slide deck was published by Cellectar Biosciences, Inc. in conjunction with this event. For further details see: Cellectar Biosciences (CLRB) Investor Presentation - Slideshow

FLORHAM PARK, N.J., March 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Japan Patent Off...

FLORHAM PARK, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will be...

Cellectar Biosciences (CLRB) shares rise nearly 5% premarket after the company talked up its cash position and posted full-year results. The company had cash and cash equivalents of $57.2M compared to $10.6M at December 31, 2019. The company believes its cash on hand ...

FLORHAM PARK, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the...

Interest in Cellectar Biosciences (CLRB) from private equity firms this week jumped this week as evidenced by several SEC Form 13G and Form 13G/A amended filings.This week, Consonance Capital Management and Sio Capital Management both filed Form 13G.Consonance's filing lists 4,...

FLORHAM PARK, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, presid...

Analysts Say These Are Penny Stocks To Buy; Do You Agree? We talk a lot about penny stocks for obvious reasons. But do you know how to find the right stocks to buy? I’m sure that if you’re like most in the stock market today, you’re searching for volatility. We ...

The EMA has adopted a positive opinion for Cellectar Biosciences' (CLRB) CLR 131 orphan designation for the treatment of Waldenstrom’s Macroglobulinemia ((WM)). Cellectar has initiated a pivotal trial evaluating CLR 131 in WM patients that have failed or had a suboptimal response to a ...

FLORHAM PARK, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the European Medicin...